Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Круглый стол по материалам XIX Всероссийского научно-образовательного форума «Мать и Дитя» «Современная женщина: качество жизни, здоровье, красота»
Круглый стол по материалам XIX Всероссийского научно-образовательного форума «Мать и Дитя» «Современная женщина: качество жизни, здоровье, красота»
Круглый стол по материалам XIX Всероссийского научно-образовательного форума «Мать и Дитя» «Современная женщина: качество жизни, здоровье, красота». Гинекология. 2018; 20 (5): 15–17.
DOI: 10.26442/2079-5696_2018.5.15-17
DOI: 10.26442/2079-5696_2018.5.15-17
DOI: 10.26442/2079-5696_2018.5.15-17
________________________________________________
DOI: 10.26442/2079-5696_2018.5.15-17
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Kerscher M. Effects of an oral contraceptive containing chlormadinone acetate and ethinylestradiol on hair and skin quality in women wishing to use hormonal contraception. J Eur Acad Dermatol Venereol 2013; 27 (5): 601–8.
2. Аганезова Н.В., Аганезов С.С. Комбинированные оральные контрацептивы: не только контрацепция. Акуш. и гинекол. 2015; 6: 118–23. / Aganezova N.V., Aganezov S.S. Kombinirovannye oral'nye kontratseptivy: ne tol'ko kontratseptsiia. Akush. i ginekol. 2015; 6: 118–23. [in Russian]
3. Reid RL, Westhoff C, Mansour D et al. Oral contraceptives and venous thromboembolism. Consensus opinion from an international workshop held in Berlin, Germany in December 2009. J Fam Plann Reprod Health Care 2010; 36: 117–22.
4. Прилепская В.Н., Межевитинова Е.А., Куземин А.А. Контрацепция и гиперандрогения. Клинические эффекты препарата, содержащего хлормадинона ацетат. Гинекология. 2015; 17 (4): 4–8. / Prilepskaya V.N., Mezhevitinovа E.A., Kuzemin A.A. Contraception and hyperandrogenism. Clinical effects of a drug containing chlormadinone acetate. Gynecology. 2015; 17 (4): 4–8. [in Russian]
5. Oral contraceptive containing chlormadinone acetate and ethinylestradiol reduces plasma concentrations of matrix metalloproteinase-2 in women with polycystic ovary syndrome. Gomes VA Basic Clin Pharmacol Toxicol 2012; 111 (3): 211–6.
6. Zahradnik HP, Hanjalic-Beck. Ecacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage – an open-label, prospective, noncontrolled, oce-based Phase III study. Contraception 2008; 77 (5): 337–43.
7. Jaisamrarn U, Santibenchakul S. A comparison of combined oral contraceptives containing chlormadinone acetate versus drospirenone for the treatment of acne and dysmenorrhea: a randomized trial. Contracept Reprod Med 2018; 3: 5.
8. Plewig G, Cunliffe WJ, Binder N et al. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled phase III trial. Contraception 2009; 80 (1): 25–33.
9. Зильберберг Н.В., Толстая А.И. Оценка эффективности и безопасности препарата Белара в комплексной терапии больных акне. Фарматека. 2015; с. 40–5. / Zil'berberg N.V., Tolstaia A.I. Otsenka effektivnosti i bezopasnosti preparata Belara v kompleksnoi terapii bol'nykh akne. Farmateka. 2015; s. 40–5. [in Russian]
10. Anthuber S, Schramm GA, Heskamp ML. Six-month evaluation of the benefits of the low-dose combined oral contraceptive chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg in young women: results of the prospective, observational, non-interventional, multicentre TeeNIS study. Clin Drug Invest 2010; 30 (4): 211–20.
2. Aganezova N.V., Aganezov S.S. Kombinirovannye oral'nye kontratseptivy: ne tol'ko kontratseptsiia. Akush. i ginekol. 2015; 6: 118–23. [in Russian]
3. Reid RL, Westhoff C, Mansour D et al. Oral contraceptives and venous thromboembolism. Consensus opinion from an international workshop held in Berlin, Germany in December 2009. J Fam Plann Reprod Health Care 2010; 36: 117–22.
4. Prilepskaya V.N., Mezhevitinovа E.A., Kuzemin A.A. Contraception and hyperandrogenism. Clinical effects of a drug containing chlormadinone acetate. Gynecology. 2015; 17 (4): 4–8. [in Russian]
5. Oral contraceptive containing chlormadinone acetate and ethinylestradiol reduces plasma concentrations of matrix metalloproteinase-2 in women with polycystic ovary syndrome. Gomes VA Basic Clin Pharmacol Toxicol 2012; 111 (3): 211–6.
6. Zahradnik HP, Hanjalic-Beck. Ecacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage – an open-label, prospective, noncontrolled, oce-based Phase III study. Contraception 2008; 77 (5): 337–43.
7. Jaisamrarn U, Santibenchakul S. A comparison of combined oral contraceptives containing chlormadinone acetate versus drospirenone for the treatment of acne and dysmenorrhea: a randomized trial. Contracept Reprod Med 2018; 3: 5.
8. Plewig G, Cunliffe WJ, Binder N et al. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled phase III trial. Contraception 2009; 80 (1): 25–33.
9. Zil'berberg N.V., Tolstaia A.I. Otsenka effektivnosti i bezopasnosti preparata Belara v kompleksnoi terapii bol'nykh akne. Farmateka. 2015; s. 40–5. [in Russian]
10. Anthuber S, Schramm GA, Heskamp ML. Six-month evaluation of the benefits of the low-dose combined oral contraceptive chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg in young women: results of the prospective, observational, non-interventional, multicentre TeeNIS study. Clin Drug Invest 2010; 30 (4): 211–20.
2. Аганезова Н.В., Аганезов С.С. Комбинированные оральные контрацептивы: не только контрацепция. Акуш. и гинекол. 2015; 6: 118–23. / Aganezova N.V., Aganezov S.S. Kombinirovannye oral'nye kontratseptivy: ne tol'ko kontratseptsiia. Akush. i ginekol. 2015; 6: 118–23. [in Russian]
3. Reid RL, Westhoff C, Mansour D et al. Oral contraceptives and venous thromboembolism. Consensus opinion from an international workshop held in Berlin, Germany in December 2009. J Fam Plann Reprod Health Care 2010; 36: 117–22.
4. Прилепская В.Н., Межевитинова Е.А., Куземин А.А. Контрацепция и гиперандрогения. Клинические эффекты препарата, содержащего хлормадинона ацетат. Гинекология. 2015; 17 (4): 4–8. / Prilepskaya V.N., Mezhevitinovа E.A., Kuzemin A.A. Contraception and hyperandrogenism. Clinical effects of a drug containing chlormadinone acetate. Gynecology. 2015; 17 (4): 4–8. [in Russian]
5. Oral contraceptive containing chlormadinone acetate and ethinylestradiol reduces plasma concentrations of matrix metalloproteinase-2 in women with polycystic ovary syndrome. Gomes VA Basic Clin Pharmacol Toxicol 2012; 111 (3): 211–6.
6. Zahradnik HP, Hanjalic-Beck. Ecacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage – an open-label, prospective, noncontrolled, oce-based Phase III study. Contraception 2008; 77 (5): 337–43.
7. Jaisamrarn U, Santibenchakul S. A comparison of combined oral contraceptives containing chlormadinone acetate versus drospirenone for the treatment of acne and dysmenorrhea: a randomized trial. Contracept Reprod Med 2018; 3: 5.
8. Plewig G, Cunliffe WJ, Binder N et al. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled phase III trial. Contraception 2009; 80 (1): 25–33.
9. Зильберберг Н.В., Толстая А.И. Оценка эффективности и безопасности препарата Белара в комплексной терапии больных акне. Фарматека. 2015; с. 40–5. / Zil'berberg N.V., Tolstaia A.I. Otsenka effektivnosti i bezopasnosti preparata Belara v kompleksnoi terapii bol'nykh akne. Farmateka. 2015; s. 40–5. [in Russian]
10. Anthuber S, Schramm GA, Heskamp ML. Six-month evaluation of the benefits of the low-dose combined oral contraceptive chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg in young women: results of the prospective, observational, non-interventional, multicentre TeeNIS study. Clin Drug Invest 2010; 30 (4): 211–20.
________________________________________________
2. Aganezova N.V., Aganezov S.S. Kombinirovannye oral'nye kontratseptivy: ne tol'ko kontratseptsiia. Akush. i ginekol. 2015; 6: 118–23. [in Russian]
3. Reid RL, Westhoff C, Mansour D et al. Oral contraceptives and venous thromboembolism. Consensus opinion from an international workshop held in Berlin, Germany in December 2009. J Fam Plann Reprod Health Care 2010; 36: 117–22.
4. Prilepskaya V.N., Mezhevitinovа E.A., Kuzemin A.A. Contraception and hyperandrogenism. Clinical effects of a drug containing chlormadinone acetate. Gynecology. 2015; 17 (4): 4–8. [in Russian]
5. Oral contraceptive containing chlormadinone acetate and ethinylestradiol reduces plasma concentrations of matrix metalloproteinase-2 in women with polycystic ovary syndrome. Gomes VA Basic Clin Pharmacol Toxicol 2012; 111 (3): 211–6.
6. Zahradnik HP, Hanjalic-Beck. Ecacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage – an open-label, prospective, noncontrolled, oce-based Phase III study. Contraception 2008; 77 (5): 337–43.
7. Jaisamrarn U, Santibenchakul S. A comparison of combined oral contraceptives containing chlormadinone acetate versus drospirenone for the treatment of acne and dysmenorrhea: a randomized trial. Contracept Reprod Med 2018; 3: 5.
8. Plewig G, Cunliffe WJ, Binder N et al. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled phase III trial. Contraception 2009; 80 (1): 25–33.
9. Zil'berberg N.V., Tolstaia A.I. Otsenka effektivnosti i bezopasnosti preparata Belara v kompleksnoi terapii bol'nykh akne. Farmateka. 2015; s. 40–5. [in Russian]
10. Anthuber S, Schramm GA, Heskamp ML. Six-month evaluation of the benefits of the low-dose combined oral contraceptive chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg in young women: results of the prospective, observational, non-interventional, multicentre TeeNIS study. Clin Drug Invest 2010; 30 (4): 211–20.
Авторы
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.